Clinical outcome and prognosis of patients with primary sinonasal tract diffuse large B-cell lymphoma treated with rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy: a study by the Consortium for Improving Survival of Lymphoma

• Published in: Leukemia & lymphoma 2015-04, Vol.56 (4), p.1020-1026
• Main Authors: Lee, Gyeong-Won, Go, Se-Il, Kim, Seok-Hyun, Hong, Junshik, Kim, Yu Ri, Oh, Sukjoong, Kim, Sung-Yong, Do, Young Rok, Lee, Hyewon, Lee, Soon Il, Bae, Sung Hwa, Oh, Sung Yong, Song, Moo Kon, Lee, Won-Sik, Lee, Bohee, Kim, Jin Seok, Kim, Min Kyoung, Kang, Hye Jin, Ahn, Jae-Sook, Yhim, Ho-Young, Kim, Hyo Jung, Kim, Seok Jin, Kim, Won Seog, Suh, Cheolwon
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Cyclophosphamide - administration & dosage; Diffuse large cell lymphomas; Disease-Free Survival; Doxorubicin - administration & dosage; Female; Humans; Lymphoma, Large B-Cell, Diffuse - drug therapy; Lymphoma, Large B-Cell, Diffuse - pathology; Male; Middle Aged; Multivariate Analysis; nasal cavities; Neoplasm Recurrence, Local; Neoplasm Staging; paranasal sinus; Paranasal Sinus Neoplasms - drug therapy; Prednisone - administration & dosage; Prognosis; rituximab; Rituximab - administration & dosage; Treatment Outcome; Vincristine - administration & dosage
• ISSN: 1042-8194; 1029-2403
• DOI: 10.3109/10428194.2014.946027

Abstract We evaluated the clinical outcomes and relapse patterns of 80 patients with primary sinonasal tract diffuse large B-cell lymphoma (SN-DLBCL) treated with rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) chemotherapy at 22 institutions. A total of 59 (73.8%) patients received R-CHOP chemotherapy alone, whereas 21 (26.3%) were treated with R-CHOP followed by involved field radiotherapy (IFRT). In 73 patients with Ann Arbor stage I-II disease, no significant difference was found in the response rate or overall survival (OS) between R-CHOP alone (n = 52) and R-CHOP followed by IFRT (n = 21). Among 11 relapsed patients in this study, the most common pattern of relapse was local (n = 8, 11.8%), whereas central nervous system (CNS) relapse was observed in only one (1.9%) patient. These results suggest that patients with primary SN-DLBCL treated with R-CHOP have a relatively low CNS relapse rate and better OS compared to previous studies before the introduction of R.